Stay updated on Pembrolizumab in Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page’s displayed release/version label was updated from Revision v3.5.2 to Revision v3.5.3, indicating a site-level version change rather than a modification to the clinical study record.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedAdded a Medullary thyroid carcinoma topic entry and a Resources section linking to the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check48 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision metadata updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check84 days agoChange DetectedA new Revision: v3.4.2 tag was added and the previous Revision: v3.4.1 tag was removed; no study content, eligibility criteria, or navigation changes are evident.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Medullary Thyroid Cancer Clinical Trial page.